Ticagrelor Based De-Escalation of Dual Antiplatelet Therapy in Ischemic Stroke
This is a randomized, controlled, outcome assessor blind, parallel group design pilot study on 100 patient with diagnosis of ischemic stroke admitted in Bou-Ali Sina Hospital, Sari,Iran.The aim of study is to compare the efficacy of 90 mg ticagrelor BID plus aspirin for 1 month and 60 mg ticagrelor BID plus aspirin for
| Condition(s) | Ischemic Stroke, Transient Ischemic Attack |
|---|---|
| Status | Recruiting |
| Phase | Phase 2, Phase 3 |
| Study type | Interventional |
| Summary | This is a randomized, controlled, outcome assessor blind, parallel group design pilot study on 100 patient with diagnosis of ischemic stroke admitted in Bou-Ali Sina Hospital, Sari,Iran.The aim of study is to compare the efficacy of 90 mg ticagrelor BID plus aspirin for 1 month and 60 mg ticagrelor BID plus aspirin for 6 months in reduce of non-disabling non-cardioembolic ischemic stroke or high risk TIA recurrence during first 12 months. |
| Who can participate | Inclusion Criteria: * signing inform consent, * recent ischemic stroke within 24 h, * diagnosed by brain CT or MRI mild stroke with NIHSS =\<8 and no evidence of large infarct in brain imaging * high risk TIA with ABCD \>4, * no cardioembolic source such as low E/F, MS, AF ,... * no specific etiology such as dissection, vasculitis, ... * no carotid stenosis \> 50 % in side of involvement Exclusion Criteria: * history of hypersensitivity to consumptive drug * any indication for anticoagulant therapy * acute phase treatment with intravenous thrombolysis or thrombectomy * any contraindication for consumptive drug * history of intracranial hemorrhage * history of GI bleeding during past 6 m * candidate for endarterectomy * history of coagulopathy * active hemorrhagic diathesis during randomiza |
| Ages | 40 Years |
| Sex | All |
| Accepts healthy volunteers | Yes |
| Lead sponsor | Mazandaran University of Medical Sciences |
| Locations | Sari, Mazandaran, Iran |
| Start date | 2024-04-01 |
| NCT ID | NCT06653348 |
| Official listing | https://clinicaltrials.gov/study/NCT06653348 |